...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>British Journal of Haematology >Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia ( ITP ITP ) for up to 1?year and in those with chronic ITP ITP for more than 1?year: a subgroup analysis of integrated data from completed romiplostim studies
【24h】

Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia ( ITP ITP ) for up to 1?year and in those with chronic ITP ITP for more than 1?year: a subgroup analysis of integrated data from completed romiplostim studies

机译：成年患者的Romiplostim患者新诊断或持续的免疫血小板减少症（ITP ITP）最多1年，并在慢性ITP ITP的那些中超过1？一年：来自完成的romiplosim研究的综合数据亚组分析

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Summary The thrombopoietin receptor agonist romiplostim is approved for second‐line use in chronic immune thrombocytopenia ( ITP ), but its effects in patients with ITP for ≤1?year are not well characterized. This analysis of pooled data from 9 studies included patients with ITP for ≤1?year ( n? = ? 311) or 1?year ( n? = ? 726) who failed first‐line treatments and received romiplostim, placebo or standard of care. In subgroup analysis by ITP duration, patient incidences for platelet response at ≥75% of measurements were higher for romiplostim [ ITP ≤1?year: 74% (204/277); ITP 1?year: 71% (450/634)] than for placebo/standard of care [ ITP ≤1?year: 18% (6/34); ITP 1?year: 9% (8/92)]. Of patients with ≥9?months on study, 16% with ITP ≤1?year and 6% with ITP 1?year discontinued romiplostim and maintained platelet counts ≥50?×?10 9 /l for ≥6?months without ITP treatment (treatment‐free remission). Independent of ITP duration, rates of serious adverse events and bleeding were lower with romiplostim than placebo/standard of care and thrombotic events occurred at similar rates. In this analysis, romiplostim and placebo/standard of care had similar safety profiles and romiplostim increased platelet counts in patients with either ITP ≤1?year or ITP 1?year, with more treatment‐free remission in those with ITP ≤1?year.
机译：发明内容血小板生成素受体激动剂romiplosim批准用于慢性免疫血小板减少症（ITP）的二线使用，但其对ITP患者的影响≤1Δ年并不具备很好的表征。这种分析来自9项研究的汇总数据包括ITP的患者≤1？一年（n？=？311）或＆ 1？一年（n？=？726）谁失败了一线处理，收到了romiplosim，安慰剂或标准护理。在STP持续时间的亚组分析中，对于≥75％的血小板反应的患者发泄≥75％的测量对于RomiplostimIm [ITP≤1'年份：74％（204/277）; ITP＆ 1？年：71％（450/634）]比安慰剂/护理标准[ITP≤1吗？年：18％（6/34）; ITP＆ 1？年：9％（8/92）]。 ≥9岁的患者研究，ITP≤1个月，16％，ITP＆ 1？一年停止的血小板计数≥50？×10 9 / L保持≥6？治疗（无处理缓解）。独立于ITP持续时间，严重不良事件和出血的率与RomiplosimIM低于安慰剂/护理标准，血栓形成事件以类似的速率发生。在这个分析中，Romiplosim和安慰剂/护理标准具有类似的安全性曲线和血小板计数患者的血小板计数，患者患者≤1？一年或ITP＆ 1？一年，在ITP≤1的那些中有更多的治疗缓解缓解？年。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号